TIAA Trust National Association Sells 4,391 Shares of CVS Health Co. (NYSE:CVS)

TIAA Trust National Association lessened its holdings in CVS Health Co. (NYSE:CVS) by 12.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,016 shares of the pharmacy operator’s stock after selling 4,391 shares during the period. TIAA Trust National Association’s holdings in CVS Health were worth $1,392,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of CVS. Widmann Financial Services Inc. raised its holdings in CVS Health by 1.8% in the 3rd quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator’s stock valued at $724,000 after acquiring an additional 200 shares during the period. EagleClaw Capital Managment LLC lifted its holdings in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock worth $275,000 after purchasing an additional 200 shares during the last quarter. Manchester Capital Management LLC grew its holdings in CVS Health by 4.8% in the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock valued at $200,000 after buying an additional 204 shares in the last quarter. Angeles Investment Advisors LLC increased its position in CVS Health by 3.7% during the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock worth $256,000 after buying an additional 204 shares during the period. Finally, Rogco LP boosted its position in shares of CVS Health by 3.2% in the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock valued at $303,000 after acquiring an additional 210 shares during the period. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Up 0.6 %

Shares of CVS opened at $67.59 on Friday. The stock has a market capitalization of $85.22 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 0.98 and a beta of 0.54. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The stock has a fifty day moving average of $61.83 and a 200-day moving average of $57.60.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, sell-side analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.94%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s payout ratio is currently 72.68%.

Insider Transactions at CVS Health

In related news, Director Michael F. Mahoney bought 30,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Evercore ISI raised their price target on shares of CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Leerink Partners upgraded CVS Health from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Truist Financial upped their target price on CVS Health from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald raised CVS Health from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $70.39.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.